PRN1008: BTK Inhibitor Autoimmune / Inflammatory Diseases

Phase 2

Bruton’s tyrosine kinase (BTK) is a key element in the B-cell signaling pathway. The role of B-cells in autoimmunity has been clinically validated with B-cell depleting therapy including diseases like Pemphigus, Vasculitis, Immune Thrombocytopenia Purpura, Multiple Sclerosis and Rheumatoid Arthritis. The development of a fast acting, orally available therapy that could effectively and safely modulate B-cell function without depleting B-cells would be a major advancement in treating autoimmune diseases.

  • Ongoing Phase 2 clinical trial in patients with pemphigus vulgaris: 12-week open-label trial in naïve or relapsing patients

  • Pemphigus vulgaris is a rare, potentially life-threatening orphan autoimmune disease associated with painful chronic blistering of the skin

  • Successful completion of Phase 1 trials. PRN1008 has been evaluated in over 100 healthy volunteers and patients

  • BTK modulates immune cell signaling central to many components of autoimmune and inflammatory diseases